Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 6/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 6/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3989724 | 0.81 | ABL1 (0.54) | CYP3A4SMN1; SMN2POLB | |
| SCHEMBL721736 | 0.72 | CYP17A1 (0.61) | CYP11B1CYP11B2CYP17A1HRH4HRH3 | |
| SCHEMBL6929568 | 0.71 | — | — | |
| SCHEMBL6042144 | 0.71 | NOTUM (0.64) | CYP3A4MAPTSMN1; SMN2APOBEC3GHDAC6 | |
| SCHEMBL27923928 | 0.70 | DAO (0.48) | — | |
| SCHEMBL18914131 | 0.70 | KEAP1 (0.38) | — | |
| SCHEMBL14257671 | 0.70 | CYP17A1 (0.54) | CYP11B1CYP11B2CYP17A1HRH4HRH3 | |
| SCHEMBL885378 | 0.70 | — | — | |
| SCHEMBL9494732 | 0.70 | — | — | |
| SCHEMBL29183551 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745389-B2 | HDAC6 selective inhibitors, preparation method therefor, and application thereof | CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD. (CN) | 2020-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745389-B2 | HDAC6 selective inhibitors, preparation method therefor, and application thereof | HDAC6, HDAC1, HDAC11 | CYP11B1 666/4885CYP11B2 1052/4885CYP17A1 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.